Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Zika Virus Infection | 12 | 2021 | 39 | 3.100 |
Why?
|
| Macaca mulatta | 26 | 2026 | 261 | 3.070 |
Why?
|
| Antibodies, Neutralizing | 12 | 2025 | 220 | 2.750 |
Why?
|
| Antibodies, Monoclonal | 10 | 2026 | 875 | 2.450 |
Why?
|
| Antibodies, Viral | 13 | 2022 | 329 | 2.390 |
Why?
|
| Simian Immunodeficiency Virus | 14 | 2026 | 84 | 1.990 |
Why?
|
| Zika Virus | 9 | 2021 | 38 | 1.900 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 12 | 2026 | 62 | 1.670 |
Why?
|
| Histocompatibility Antigens Class I | 8 | 2026 | 143 | 1.580 |
Why?
|
| Dengue Virus | 6 | 2022 | 101 | 1.460 |
Why?
|
| Receptors, Fc | 4 | 2026 | 25 | 1.300 |
Why?
|
| Receptors, CCR5 | 3 | 2026 | 59 | 1.230 |
Why?
|
| HIV Antibodies | 7 | 2026 | 146 | 1.070 |
Why?
|
| Immunoglobulin A | 1 | 2026 | 102 | 0.890 |
Why?
|
| Dengue Vaccines | 4 | 2022 | 8 | 0.890 |
Why?
|
| Fetus | 1 | 2024 | 103 | 0.830 |
Why?
|
| SAIDS Vaccines | 6 | 2019 | 21 | 0.810 |
Why?
|
| Immunoglobulin G | 7 | 2026 | 472 | 0.790 |
Why?
|
| Dependovirus | 4 | 2026 | 760 | 0.740 |
Why?
|
| Animals | 45 | 2026 | 21467 | 0.720 |
Why?
|
| CD8-Positive T-Lymphocytes | 10 | 2021 | 679 | 0.720 |
Why?
|
| Brucellosis | 6 | 2014 | 8 | 0.680 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2025 | 80 | 0.670 |
Why?
|
| HIV Infections | 6 | 2025 | 958 | 0.640 |
Why?
|
| Neck Injuries | 1 | 2019 | 18 | 0.600 |
Why?
|
| Facial Injuries | 1 | 2019 | 13 | 0.600 |
Why?
|
| Deglutition Disorders | 1 | 2019 | 44 | 0.590 |
Why?
|
| Burns | 1 | 2019 | 46 | 0.590 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2019 | 72 | 0.570 |
Why?
|
| Plasma Cells | 1 | 2017 | 52 | 0.520 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 47 | 0.510 |
Why?
|
| Immunodominant Epitopes | 1 | 2017 | 59 | 0.500 |
Why?
|
| HIV-1 | 5 | 2025 | 707 | 0.460 |
Why?
|
| CCR5 Receptor Antagonists | 2 | 2026 | 17 | 0.450 |
Why?
|
| Animals, Newborn | 4 | 2025 | 241 | 0.440 |
Why?
|
| Viral Load | 7 | 2021 | 230 | 0.420 |
Why?
|
| Graft Rejection | 3 | 2025 | 304 | 0.410 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 389 | 0.390 |
Why?
|
| Joints | 1 | 2013 | 33 | 0.380 |
Why?
|
| Brucella melitensis | 4 | 2014 | 4 | 0.380 |
Why?
|
| Isoantibodies | 2 | 2023 | 35 | 0.370 |
Why?
|
| Bone and Bones | 1 | 2013 | 152 | 0.350 |
Why?
|
| Pregnancy | 5 | 2024 | 2393 | 0.340 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2026 | 449 | 0.340 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 1010 | 0.330 |
Why?
|
| Humans | 28 | 2026 | 65654 | 0.310 |
Why?
|
| Host-Pathogen Interactions | 3 | 2021 | 279 | 0.310 |
Why?
|
| Female | 18 | 2025 | 34310 | 0.300 |
Why?
|
| Cross Reactions | 3 | 2026 | 140 | 0.300 |
Why?
|
| Gene Products, vif | 2 | 2019 | 9 | 0.290 |
Why?
|
| Gene Products, nef | 2 | 2019 | 13 | 0.290 |
Why?
|
| Virus Replication | 3 | 2026 | 323 | 0.270 |
Why?
|
| Viremia | 4 | 2021 | 46 | 0.270 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2026 | 254 | 0.270 |
Why?
|
| Simian T-lymphotropic virus 1 | 2 | 2017 | 2 | 0.260 |
Why?
|
| Gene Products, tax | 2 | 2017 | 2 | 0.260 |
Why?
|
| Male | 14 | 2025 | 31297 | 0.250 |
Why?
|
| Immunity, Mucosal | 1 | 2026 | 53 | 0.230 |
Why?
|
| Thrombopoietin | 1 | 2025 | 11 | 0.230 |
Why?
|
| Abatacept | 1 | 2025 | 67 | 0.230 |
Why?
|
| Journal Impact Factor | 1 | 2025 | 26 | 0.220 |
Why?
|
| Transplantation Conditioning | 1 | 2025 | 101 | 0.220 |
Why?
|
| Genetic Vectors | 3 | 2026 | 929 | 0.210 |
Why?
|
| CD40 Ligand | 1 | 2025 | 159 | 0.210 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2024 | 32 | 0.210 |
Why?
|
| Kidney Transplantation | 2 | 2025 | 326 | 0.210 |
Why?
|
| Immunization, Passive | 1 | 2024 | 97 | 0.210 |
Why?
|
| Immunologic Factors | 1 | 2025 | 108 | 0.210 |
Why?
|
| Models, Animal | 2 | 2021 | 242 | 0.200 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2025 | 300 | 0.200 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 2 | 2021 | 60 | 0.200 |
Why?
|
| Flow Cytometry | 4 | 2021 | 664 | 0.200 |
Why?
|
| Antibody Affinity | 2 | 2021 | 18 | 0.200 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 1 | 1 | 2022 | 6 | 0.190 |
Why?
|
| Biomedical Research | 1 | 2025 | 263 | 0.180 |
Why?
|
| Immunoglobulin M | 2 | 2023 | 116 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2025 | 355 | 0.180 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2022 | 48 | 0.180 |
Why?
|
| Macaca | 2 | 2021 | 30 | 0.180 |
Why?
|
| Immunity, Cellular | 3 | 2017 | 170 | 0.170 |
Why?
|
| Antilymphocyte Serum | 1 | 2021 | 22 | 0.170 |
Why?
|
| Receptors, IgG | 1 | 2021 | 41 | 0.170 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 34 | 0.170 |
Why?
|
| Tissue Donors | 1 | 2021 | 147 | 0.160 |
Why?
|
| Coinfection | 1 | 2021 | 59 | 0.160 |
Why?
|
| Rectum | 2 | 2019 | 97 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2021 | 642 | 0.150 |
Why?
|
| RNA, Viral | 5 | 2019 | 266 | 0.150 |
Why?
|
| Antibody-Dependent Enhancement | 1 | 2019 | 4 | 0.150 |
Why?
|
| Immune Sera | 1 | 2019 | 35 | 0.150 |
Why?
|
| Epidemics | 1 | 2019 | 27 | 0.150 |
Why?
|
| Mice, Inbred BALB C | 4 | 2013 | 869 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2019 | 1026 | 0.140 |
Why?
|
| Gene Products, env | 1 | 2018 | 18 | 0.140 |
Why?
|
| Genetic Therapy | 1 | 2026 | 852 | 0.140 |
Why?
|
| Fetal Death | 1 | 2018 | 15 | 0.140 |
Why?
|
| HTLV-I Infections | 1 | 2017 | 3 | 0.130 |
Why?
|
| Mice | 9 | 2025 | 11174 | 0.130 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 40 | 0.130 |
Why?
|
| Herpesviridae | 1 | 2017 | 15 | 0.130 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2017 | 38 | 0.130 |
Why?
|
| Immunosuppressive Agents | 3 | 2025 | 381 | 0.130 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2017 | 117 | 0.130 |
Why?
|
| Dengue | 1 | 2017 | 98 | 0.130 |
Why?
|
| Deltaretrovirus Infections | 1 | 2016 | 2 | 0.120 |
Why?
|
| Genomics | 1 | 2019 | 386 | 0.120 |
Why?
|
| Staining and Labeling | 1 | 2016 | 127 | 0.120 |
Why?
|
| Mutation | 1 | 2024 | 2672 | 0.120 |
Why?
|
| Immune Evasion | 2 | 2017 | 71 | 0.120 |
Why?
|
| Adult | 5 | 2019 | 17511 | 0.120 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2015 | 21 | 0.110 |
Why?
|
| HEK293 Cells | 1 | 2017 | 617 | 0.110 |
Why?
|
| Drug Carriers | 1 | 2017 | 190 | 0.110 |
Why?
|
| Phylogeny | 3 | 2024 | 399 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1567 | 0.110 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 1589 | 0.100 |
Why?
|
| Macrophages | 2 | 2022 | 1041 | 0.100 |
Why?
|
| Virulence Factors | 1 | 2013 | 86 | 0.100 |
Why?
|
| Unfolded Protein Response | 1 | 2013 | 62 | 0.100 |
Why?
|
| Arthritis | 1 | 2013 | 52 | 0.090 |
Why?
|
| Transplantation, Heterologous | 2 | 2023 | 241 | 0.090 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 2327 | 0.090 |
Why?
|
| Middle Aged | 3 | 2019 | 18440 | 0.090 |
Why?
|
| Fimbriae Proteins | 1 | 2012 | 13 | 0.090 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2019 | 186 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 2730 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2019 | 3329 | 0.090 |
Why?
|
| Graft Survival | 2 | 2025 | 300 | 0.090 |
Why?
|
| Young Adult | 2 | 2019 | 4855 | 0.090 |
Why?
|
| Bone Marrow | 1 | 2013 | 176 | 0.090 |
Why?
|
| Spleen | 1 | 2013 | 476 | 0.090 |
Why?
|
| Interferon-gamma | 4 | 2017 | 576 | 0.090 |
Why?
|
| Adolescent | 2 | 2019 | 6350 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2012 | 169 | 0.090 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 105 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2017 | 604 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 273 | 0.080 |
Why?
|
| Antibody Specificity | 2 | 2021 | 103 | 0.080 |
Why?
|
| Vaccines, Attenuated | 2 | 2022 | 35 | 0.080 |
Why?
|
| Brain | 1 | 2018 | 1625 | 0.070 |
Why?
|
| Aedes | 2 | 2019 | 14 | 0.070 |
Why?
|
| Antigens, Bacterial | 1 | 2009 | 202 | 0.070 |
Why?
|
| Vaccines, Synthetic | 2 | 2019 | 80 | 0.070 |
Why?
|
| Liver | 1 | 2013 | 874 | 0.070 |
Why?
|
| Brucella abortus | 1 | 2008 | 6 | 0.070 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 741 | 0.070 |
Why?
|
| Cytokines | 2 | 2012 | 964 | 0.070 |
Why?
|
| Florida | 2 | 2017 | 46 | 0.070 |
Why?
|
| Viral Vaccines | 2 | 2019 | 56 | 0.060 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2008 | 203 | 0.060 |
Why?
|
| Disease Outbreaks | 2 | 2017 | 110 | 0.060 |
Why?
|
| Genome, Viral | 2 | 2017 | 145 | 0.060 |
Why?
|
| Macaca nemestrina | 1 | 2026 | 9 | 0.060 |
Why?
|
| Drug Discovery | 2 | 2017 | 96 | 0.060 |
Why?
|
| Immunotoxins | 1 | 2025 | 7 | 0.060 |
Why?
|
| Cell Separation | 1 | 2025 | 147 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2025 | 32 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2008 | 531 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2025 | 63 | 0.050 |
Why?
|
| Germinal Center | 1 | 2025 | 40 | 0.050 |
Why?
|
| Animals, Genetically Modified | 1 | 2025 | 312 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2025 | 186 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2016 | 194 | 0.050 |
Why?
|
| Vaccination | 2 | 2019 | 388 | 0.050 |
Why?
|
| Incidence | 2 | 2019 | 1432 | 0.050 |
Why?
|
| United States | 1 | 2017 | 8166 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2025 | 518 | 0.050 |
Why?
|
| Primates | 1 | 2024 | 52 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2023 | 62 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 797 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2025 | 222 | 0.050 |
Why?
|
| Brazil | 1 | 2022 | 104 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2025 | 565 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2022 | 147 | 0.040 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2021 | 34 | 0.040 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2021 | 27 | 0.040 |
Why?
|
| Swine | 1 | 2022 | 397 | 0.040 |
Why?
|
| Histocompatibility Testing | 1 | 2021 | 32 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2021 | 26 | 0.040 |
Why?
|
| Glycosylation | 1 | 2021 | 139 | 0.040 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2021 | 16 | 0.040 |
Why?
|
| Age Factors | 1 | 2025 | 1592 | 0.040 |
Why?
|
| Vero Cells | 1 | 2021 | 81 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2021 | 85 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2021 | 201 | 0.040 |
Why?
|
| Cuba | 1 | 2019 | 1 | 0.040 |
Why?
|
| West Indies | 1 | 2019 | 6 | 0.040 |
Why?
|
| Mosquito Control | 1 | 2019 | 8 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2019 | 22 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 72 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 709 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2019 | 52 | 0.040 |
Why?
|
| Kinetics | 1 | 2021 | 757 | 0.040 |
Why?
|
| Travel | 1 | 2019 | 44 | 0.040 |
Why?
|
| Genotype | 1 | 2021 | 674 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 182 | 0.030 |
Why?
|
| Papio anubis | 1 | 2017 | 2 | 0.030 |
Why?
|
| Exanthema | 1 | 2017 | 28 | 0.030 |
Why?
|
| Americas | 1 | 2017 | 6 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2019 | 274 | 0.030 |
Why?
|
| Asia | 1 | 2017 | 25 | 0.030 |
Why?
|
| Caribbean Region | 1 | 2017 | 21 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2017 | 31 | 0.030 |
Why?
|
| Africa | 1 | 2017 | 30 | 0.030 |
Why?
|
| Mosquito Vectors | 1 | 2017 | 17 | 0.030 |
Why?
|
| Nervous System Malformations | 1 | 2017 | 12 | 0.030 |
Why?
|
| Disease Transmission, Infectious | 1 | 2017 | 20 | 0.030 |
Why?
|
| Viral Envelope Proteins | 1 | 2017 | 102 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 51 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2017 | 40 | 0.030 |
Why?
|
| Alleles | 1 | 2018 | 455 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 238 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2017 | 90 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2017 | 232 | 0.030 |
Why?
|
| Papio | 1 | 2016 | 22 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2017 | 5820 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 514 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2013 | 2168 | 0.030 |
Why?
|
| HLA-B27 Antigen | 1 | 2015 | 3 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 316 | 0.030 |
Why?
|
| Viral Proteins | 1 | 2017 | 272 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1487 | 0.030 |
Why?
|
| Proteome | 1 | 2016 | 153 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 213 | 0.030 |
Why?
|
| DNA Primers | 1 | 2015 | 302 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 542 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2016 | 284 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 417 | 0.030 |
Why?
|
| Microbial Viability | 1 | 2013 | 56 | 0.030 |
Why?
|
| Base Sequence | 1 | 2015 | 1331 | 0.020 |
Why?
|
| Peptides | 1 | 2016 | 593 | 0.020 |
Why?
|
| Dogs | 1 | 2013 | 326 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 1979 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2017 | 2076 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2012 | 167 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2639 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 606 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 2009 | 85 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2193 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2009 | 181 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 2262 | 0.020 |
Why?
|
| Epitopes | 1 | 2009 | 291 | 0.020 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2008 | 18 | 0.020 |
Why?
|
| Child | 1 | 2017 | 4634 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2008 | 127 | 0.020 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2008 | 219 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2008 | 237 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2008 | 207 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 3501 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2008 | 350 | 0.010 |
Why?
|
| Protein Binding | 1 | 2009 | 1636 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 1634 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 15090 | 0.010 |
Why?
|